BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class ...
アンジオテンシン（AT1）受容体拮抗作用に加え、血管収縮作用のあるエンドセリン（ETA）の受容体拮抗作用も併せ持つ新規降圧薬「Dual Acting Angiotensin and Endothelin Receptor Antagonist（DARA）」（薬剤の開発番号：PS433540）のフェーズ2bの臨床試験の結果が、第24回 ...
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class ...
Telmisartan (Micardis, Boehringer Ingelheim), a nonpeptide AT-II-receptor antagonist, gained FDA approval for use in the treatment of hypertension in 1998. After oral administration, peak ...
Research that focused on blocking the renin-angiotensin system (RAS) led to the discovery of ACE inhibitors, which proved efficacious in the treatment of hypertension, various cardiovascular disorders ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する